Terminal › Stocks › ANVS

Annovis Bio, Inc. (ANVS) Stock

Healthcare · Biotechnology · US

$1.62 -29.57%

Last updated Jun 19, 2026 00:02 UTC

ANVS Key Statistics

Market Cap$31.87M

P/E (TTM)-1.05

P/S (TTM)—

P/B (TTM)2.39

Revenue (TTM)$0.00

EPS (TTM)$-1.54

Dividend Yield—

ROE (TTM)-159.43%

Net Margin0.00%

Gross Margin0.00%

52W High$3.03

52W Low$1.61

Analyst ViewBuy

Price Target$25.67

Employees8

Volume6,640,759

About Annovis Bio, Inc.

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.

CEO: Maria L. Maccecchini. Company website

See ANVS live in QFI Terminal

Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.

Open ANVS in Terminal See plans

More Healthcare stocks

UNH UnitedHealth Group Incorporated CVS CVS Health Corporation MCK McKesson Corporation COR Cencora, Inc. NVO Novo Nordisk A/S CI Cigna Corporation CAH Cardinal Health, Inc. ELV Elevance Health Inc.